Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study

被引：0
|
作者：
Gabriela Grimaldi
Giuseppe Cancian
Angelica Rizzato
Alex Casanova
Kathrin Perruchoud-Ader
Michele Clerici
Andrea Consigli
Moreno Menghini
机构：
[1] Ente Ospedaliero Cantonale (EOC),Department of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI)
来源：
Graefe's Archive for Clinical and Experimental Ophthalmology | 2024年 / 262卷
关键词：
Faricimab; Age-related macular degeneration; Treat-and-extend; Real-world data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1151 / 1159
页数：8
相关论文
共 50 条
  • [31] Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy
    Szigiato, Andrei
    Mohan, Nitesh
    Talcott, Katherine E.
    Mammo, Danny A.
    Babiuch, Amy S.
    Kaiser, Peter K.
    Ehlers, Justis P.
    Rachitskaya, Aleksandra
    Yuan, Alex
    Srivastava, Sunil K.
    Sharma, Sumit
    [J]. OPHTHALMOLOGY, 2024, 131 (02) : 128 - 129
  • [32] Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy
    Szigiato, Andrei
    Mohan, Nitesh
    Talcott, Katherine E.
    Mammo, Danny A.
    Babiuch, Amy S.
    Kaiser, Peter K.
    Ehlers, Justis P.
    Rachitskaya, Aleksandra
    Yuan, Alex
    Srivastava, Sunil K.
    Sharma, Sumit
    [J]. OPHTHALMOLOGY RETINA, 2024, 8 (01): : 10 - 17
  • [33] Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview
    Semeraro, Francesco
    Morescalchi, Francesco
    Duse, Sarah
    Gambicorti, Elena
    Romano, Mario R.
    Costagliola, Ciro
    [J]. EXPERT OPINION ON DRUG SAFETY, 2014, 13 (06) : 785 - 802
  • [34] The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
    Arshad M. Khanani
    Aamir A. Aziz
    Hannah Khan
    Ashwin Gupta
    Ohidul Mojumder
    Aigerim Saulebayeva
    Ashkan M. Abbey
    David R. P. Almeida
    Robert L. Avery
    Himanshu K. Banda
    Mark R. Barakat
    Ramanath Bhandari
    Emmanuel Y. Chang
    Sara J. Haug
    Nikolas J. S. London
    Luke Mein
    Veeral S. Sheth
    Jeremy D. Wolfe
    Michael A. Singer
    Carl J. Danzig
    [J]. Eye, 2023, 37 : 3574 - 3581
  • [35] Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update
    Costagliola, Ciro
    Morescalchi, Francesco
    Duse, Sarah
    Romano, Davide
    Mazza, Giuseppina
    Parmeggiani, Francesco
    Bartollino, Silvia
    Semeraro, Francesco
    [J]. EXPERT OPINION ON DRUG SAFETY, 2019, 18 (09) : 803 - 815
  • [36] Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: Therapeutic Strategies
    [J]. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2012, 229 (05) : 541 - 547
  • [37] Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
    Rush, Ryan B.
    Rush, Sloan W.
    [J]. CLINICAL OPHTHALMOLOGY, 2022, 16 : 4041 - 4046
  • [38] Adjuvant radiotherapy during anti-VEGF in neovascular age-related macular degeneration
    Rating, P.
    Freimuth, M. -A.
    Stuschke, M.
    Bornfeld, N.
    [J]. OPHTHALMOLOGE, 2017, 114 (04): : 370 - 374
  • [39] Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
    Finger, Robert P.
    Wickremasinghe, Sanjeewa S.
    Baird, Paul N.
    Guymer, Robyn H.
    [J]. SURVEY OF OPHTHALMOLOGY, 2014, 59 (01) : 1 - 18
  • [40] Factors Involved in Anti-VEGF Treatment Decisions for Neovascular Age-Related Macular Degeneration: Insights from Real-World Clinical Practice
    Yiu, Glenn
    Gulati, Shilpa
    Higgins, Victoria
    Coak, Emily
    Mascia, Daniel
    Kim, Eunice
    Spicer, Galin
    Tabano, David
    [J]. CLINICAL OPHTHALMOLOGY, 2024, 18 : 1679 - 1690
12345